SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SEALSQ Corp. is a holding company, which engages in the security of microcontrollers. It operates through the following geographical segments: North America, Europe, Middle East, Africa, Asia Pacific, and Latin America. It focuses on authentication process, digital certification, and covering individual patents of semiconductors. The company was founded on April 1, 2022 and is headquartered in Cointrin, Switzerland.

SEALSQ Corp

SEALSQ is trending following news of a collaboration to enhance cybersecurity for North America's energy infrastructure, with community members highlighting its potential in the quantum security space. Discussions revolve around the stock's potential to reach double digits, with some suggesting it is undervalued compared to its peers. Some investors believe $LAES is primed for significant growth due to its positioning in the burgeoning quantum computing and AI sectors.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending as investors discuss a potential short squeeze and the company's strategic shift toward AI data centers, particularly following a significant note offering to fund expansion. Community members are actively debating price targets, technical resistance levels, and the impact of high short interest. Bullish sentiment is fueled by the Google-backed AI data center deal and anticipation of future contracts.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending as investors discuss the possibility of a company sale following a letter from a major shareholder, Shah Capital, expressing dissatisfaction with COVID vaccine sales. The community speculates on potential buyout offers from Sanofi or Merck, with some aiming for a price of $25 or higher per share. Discussions also involve the potential of Novavax's Matrix-M adjuvant and the need for a CEO with a clear plan.

Trilogy Metals, Inc. engages in the development and exploration of mineral properties. The firm holds interests in the Upper Kobuk mineral projects that include the Arctic, a copper-zinc-lead-gold-silver and Bornite, a carbonate-hosted copper projects, which is located in the Ambler mining district in Northwest Alaska. The company was founded on April 27, 2011 and is headquartered in Vancouver, Canada.

Trilogy Metals Inc

Trilogy Metals is trending due to a recent government investment, sparking significant community discussion around the company's potential and the strategic importance of domestic mineral sourcing. Community members are actively discussing options trading, potential short squeezes, and the possibility of further gains, while also noting the company's connection to critical minerals and government initiatives. The stock's surge has triggered both excitement and caution, with some highlighting the potential for volatility.

American Resources Corp. engages in the extraction, processing, transportation, and distribution of metallurgical coal to the steel industry. It focuses on the operation of coal mining complexes located primarily within Pike, Knott, and Letcher Counties, Kentucky, and Wyoming County, West Virginia. The company was founded in 2006 and in headquartered in Fishers, IN.

American Resources Corporation - Ordinary Shares - Class A

American Resources Corporation ($AREC) is trending due to recent retail interest and news of a $33 million equity deal to fund rare earth initiatives. Community members are discussing the company's potential in the rare earth and critical minerals sector, drawing comparisons to other soaring stocks in the industry. Some investors are speculating about a potential ReElement IPO and the impact of government backing on the company.

Greenwave Technology Solutions, Inc. is an emerging growth company, which engages in recycling ferrous metal. It also recycles nonferrous metals including aluminum, copper, stainless steel, nickel, brass, titanium, lead, alloys, and mixed metal products. The company was founded on April 26, 2013 and is headquartered in Chesapeake, VA.

Greenwave Technology Solutions Inc

GWAV is experiencing significant volatility, driving interest in the stock. The community is actively debating a potential short squeeze amid a low float, while others express concern regarding the company's fundamentals and past dilution. Revenue growth and government funding related to rare earth metals are also being mentioned as potential catalysts.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. It focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan Chase is trending following the release of its Q3 earnings report, with discussion centering on the bank's performance relative to expectations and broader economic implications. Community members are weighing in on whether the initial market reaction represents a buying opportunity or a signal of underlying weakness, particularly in light of CEO Jamie Dimon's cautious outlook.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

NVTS is trending due to news of supporting NVIDIA's next-generation AI factory computing platforms, sparking excitement around its role in AI infrastructure. The community is discussing potential short squeezes and long-term growth, while also weighing caution after a significant price jump. Some believe NVTS could be the next big player in the AI-driven semiconductor sector.

Federal National Mortgage Association is a government-sponsored company, which engages in the provision of liquidity for purchases of homes and financing of multifamily rental housing and refinancing existing mortgages. It operates through the Single-Family and Multifamily segments. The Single-Family segment offers liquidity to the mortgage market and increases the availability and affordability of housing for single families. The Multifamily segment includes guaranty fees on mortgages and on multifamily mortgage loans. The company was founded in 1938 and is headquartered in Washington, DC.

Federal National Mortgage Association

FNMA is trending as investors react to mixed signals, including a recent pullback despite long-term optimism. Community discussions revolve around potential government actions, IPO timing, and the impact on common shareholders, with some expressing frustration over market manipulation.  Bullish sentiment persists due to the potential for government action and the possibility of a major IPO.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

CADL is trending amid community discussion regarding a recent term loan facility; while some express disappointment over the lack of a partnership and concerns about the loan's interest rate given the company's revenue status, others view it as a positive sign of confidence in the company's prospects and a better alternative to dilution. The community is also focused on upcoming data releases and potential catalysts, including a possible buyout.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Upstream Bio (UPB) shares saw an increase in after-hours trading on Friday following the company's presentation of pharmacology modeling data, which showed investigational antibody verekitug as potentially more potent than tezepelumab by targeting the TSLP receptor rather than its ligand.Shares of the company finished at $11.36, down by 1.7%, but rose to $11.41 in after-hours trading with a 0.4% gain.Results from the European Academy of Allergy &amp; Clinical Immunology Congress demonstrated that verekitug produced lasting and thorough blockage of the TSLP/TSLPR complex, which drives critical inflammatory diseases, including severe asthma, as well as COPD and chronic rhinosinusitis with nasal polyps (CRSwNP).The FDA-approved antibody Tezspire (tezepelumab), which targets severe asthma, operates through TSLP ligand inhibition and was developed jointly by AstraZeneca and Amgen.The modeling study used a mechanistic PK/PD approach and incorporated clinical and published data.&nbsp;Simulations predicted that verekitug would lead to a greater reduction in fractional exhaled nitric oxide (FeNO)—a biomarker for airway inflammation—compared to tezepelumab.The company is looking to assess top-line Phase 2 data in CRSwNP later this year, and in severe asthma in the first half of 2026.”Verekitug is the only known monoclonal antibody in clinical development that directly targets the TSLP receptor, offering what the company describes as a more upstream and durable blockade of the inflammatory cascade.The stock moved higher after the release, with investors responding positively to the strengthened differentiation case for verekitug as it advances through multiple Phase 2 trials.&nbsp;These include the Valiant study in severe asthma, the Vibrant trial in CRSwNP, and a planned trial in COPD.Upstream Bio previously reported favorable tolerability, high subcutaneous bioavailability, and a consistent pharmacokinetic profile for verekitug in completed Phase 1 studies.On Stocktwits, retail sentiment was ‘neutral’ amid ‘high’ message volume.Upstream’s stock has declined 30.3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Portrait of a doctor woman on the background of stock charts. | Image source: Getty Images

Upstream Bio Stock Gets A Boost As New Lung Inflammation Drug Shows Higher Potency

The company is progressing with multiple Phase 2 trials for its investigational treatment targeting severe respiratory diseases.

Equity

Automotive Security Leaders Must Take Immediate Action to Mitigate the Surging Cyber Threats--Upstream Report Reveals Critical Gaps

Automotive Security Leaders Must Take Immediate Action to Mitigate the Surging Cyber Threats--Upstream Report Reveals Critical Gaps Automotive Security Leaders Must Take Immediate Action to Mitigate...

Upstream Bio, Inc. is a clinical-stage biotechnology company, which engages in the development of treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It develops verekitug, the only known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin. The company was founded in April 2021 and is headquartered in Waltham, MA.

Upstream Bio Inc.

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Current Price	$19.85
Prev Close	$20.08
Open	$20.43
Dividend Yield	0.00%
50-Day Moving Average	$17.73
Beta	1.15
Avg. Volume	613,925.00
PE Ratio	-9.79

52-Week High	$29.46
52-Week Low	$5.14
Market Capitalization	$1.08B
EPS (Annual)	-$1.43
Price to Book	2.64
Revenue Per Employee	$45,576.92
Enterprise Value/EBITDA	N/A

UPB
Upstream Bio Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest UPB News

UPBUpstream Bio Inc.